N/A N=222 Asthma Express: Bridging the Emergency to Primary Care in Underserved Children
Asthma
Primary: Symptom Days — 6.24; 4.82 symptom days over past 14 days — p=0.06
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=2,098 Using Computers to Assist in the Treatment of Asthma in a Pediatric Setting
Asthma
Primary: Diagnosis Rate of Asthma — 54; 87 Participants
N/A N=66 Academic Achievement in Children With Asthma
Asthma
Primary: GPA — 2.75; 2.61; 3.25; 2.50 GPA(unweighted)
Phase 3 N=421 Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)
Asthma
Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3 — 9.53; 9.15 Percent Change
N/A N=152 Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma
Asthma
Primary: Number of Inhaled Corticosteroid (ICS) Prescriptions Refilled (Confirmed by Primary Care Physician) — 18; 32 Participants — p=0.87
Phase 3 N=103 Albuterol HFA MDI in Pediatric Participants With Asthma
Asthma
Primary: Maximum Percent Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Observed up to Two Hours Post Dose (FEV1max%0-2) on Day 22 — 12.849; 9.353…
Phase 4 N=52 Positive Expiratory Pressure for the Treatment of Acute Asthma in Children
Asthma
Primary: Change in Pulmonary Asthma Score (PAS) — 0.9; 0.4 mean PAS score
N/A N=55 Progression of Airway Obstruction in Childhood Asthma
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
N/A N=398 Reducing Asthma Morbidity In High Risk Minority Preschool Children
Asthma
Primary: Asthma Control as Determined by Test for Respiratory and Asthma Control in Kids Assessment Tool — 70; 75; 85; 80 score on a scale
N/A N=351 Allergens in Inner-City Schools and Childhood Asthma
Asthma
Primary: Maximum Symptom Days/14 Days — 2.7 days
Phase 3 N=945 The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room
Status Asthmaticus
Primary: Patients Hospitalization Rate — 82; 75 participants
N/A N=530 School-based Asthma Therapy: Stage 2 Effectiveness Study
Asthma
Primary: Number of Symptom Free Days — 10.7; 11.6 Days
Phase 4 N=222 An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma
Asthma
Primary: Percentage of Participants From Each Stratum Who Demonstrated Correct Use of the ELLIPTA DPI at Visit 2, Attempt 1 (Day 28) — 92; 93 Percentage of participants
N/A N=101,437 Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients
Asthma
Primary: Mean Ratio of Controller Medication to Total Asthma Medication — 0.57; 0.66; 0.66; 0.71 ratio
N/A N=16 Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study
Acute Asthma
Primary: %FEV1 — 20; 34; 26; 31 %-predicted
N/A N=292 Asthma in Central Texas Project
Asthma
Primary: Absenteeism, End of Study — 3.83; 4.41; 3.68 percentage of days enrolled
Phase 3 N=308 Use of Dexamethasone in Pediatric Asthma Exacerbations
Asthma
Primary: Number of Participants Returning to Care Following Discharge From the Emergency Department — 14; 12 Participants
N/A N=28 Pediatric Ease of Use ELLIPTA Items
Asthma
Primary: Number of Pediatric Participants With Problems Understanding Item Wording-Round 1 Interviews — 0; 0 Participants
N/A N=373 Coordinated Healthcare Interventions for Childhood Asthma Gaps in Outcomes
Asthma
Primary: PROMIS Asthma Impact Scale (v1.0, SF8a) — -7.8; -9.3; -11.9 T-score
Phase 3 N=1,771 Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)
Asthma
Primary: Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period — 0.99; 1.06; 1.05 Asthma attacks within episodes per year — p=0.510
N/A N=926 Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children
Asthma
Primary: Patient Quality of Life (QOL), Compared Mean QOL Change From Baseline at Each Follow-up Assessment Between the Clinics Assigned to the Intensive and Standard e-AT…
Phase 4 N=13 ED-Initiated School-based Asthma Medication Supervision
Asthma · Asthma in Children
Primary: 90-day Emergency Department (ED) Recidivism — 1; 2 Participants
Phase 4 N=445 Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolled Asthma (0476-385)
Asthma
Primary: Asthma Control Questionnaire (ACQ) — 328; 159; 96; 91 Participants — p=<0.001
N/A N=29 Aligning With Schools To Help Manage Asthma (Project ASTHMA)
Asthma
Primary: Change in Number of Days Per Week, in the Previous 4 Weeks, of Daytime Asthma Symptoms From Baseline to 7-month Follow-up — -3.4; -2.8 days per week
Phase 2 N=68 Symptom Clusters in Children With Exacerbation-prone Asthma
Asthma in Children
Primary: Change in Asthma Control Questionnaire (ACQ) Score — 0.52 score on a scale
Phase 4 N=257 Treatment Of Symptomatic Asthma In Children
Asthma
Primary: Percentage of Symptom-free Days During the Last 10 Weeks of the Treatment Period — 50.45; 49.75 percentage of days — p=0.63
Phase 4 N=49 Intramuscular Epinephrine as an Adjunctive Treatment for Severe Pediatric Asthma Exacerbation
Asthma
Primary: Change in Percent of Predicted Peak Expiratory Flow Rate (PEFR) at t15 — 59.56; 52.45 percentage of predicted
Phase 3 N=197 A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma
Asthma
Primary: Change From Baseline to Visit 4 in the Mean Daily Composite Score Based on the Pediatric Asthma Caregiver Assessments (PACA) — -1.21; -0.67; -0.52 units on a scale
Phase 3 N=300 Individualized Therapy For Asthma in Toddlers
Asthma · Wheezing
Primary: Differential Response to the Three Therapies Based on Fixed Threshold Criteria for the Following Asthma Control Measures: Use of Oral Prednisone for Acute Asthma…
N/A N=359 Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement
Asthma
Primary: Number of Participants Achieving Asthma Control — 121; 128; 53; 36 Participants